Bleeding risk of tirofiban, a nonpeptide GPIIb/IIIa platelet receptor antagonist in progressive stroke: an open pilot study.
Cerebrovasc Dis
; 12(4): 308-12, 2001.
Article
de En
| MEDLINE
| ID: mdl-11721100
ABSTRACT
BACKGROUND:
Glycoprotein (gp) IIb/IIIa-receptor antagonists are highly effective antiplatelet agents with proven efficacy in the treatment of acute coronary and experimental cerebral ischemia. In this study we examined the rate of hemorrhagic transformation and major bleedings in patients with acute stroke treated with tirofiban, a nonpeptide gpIIb/IIIa antagonist.METHODS:
Eighteen patients with progressively deteriorating acute ischemic stroke were treated with body-weight adjusted intravenous tirofiban for a mean period of 46 h and compared with a matched group of 17 acute ischemic clinically stable stroke patients. Cerebral hemorrhage was assessed by cranial imaging 6-10 days after symptom onset.RESULTS:
No major intracranial hemorrhage was observed in either group. Clinically asymptomatic hemorrhagic infarctions type I/II/III were detected in 4/2/0 controls and in 4/1/1 patients of the tirofiban group, respectively (OR = 0.92; 95% CI 0.4-2.5). Clinical outcome scores were not different in both groups (p = 0.18).CONCLUSIONS:
Tirofiban was not associated with a significantly increased cerebral bleeding rate in acute ischemic stroke. Randomized multicenter studies are needed to further evaluate the safety and efficacy of tirofiban in the treatment of acute stroke.
Recherche sur Google
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Tyrosine
/
Hémorragie cérébrale
/
Complexe glycoprotéique IIb-IIIa de la membrane plaquettaire
/
Accident vasculaire cérébral
/
Fibrinolytiques
Type d'étude:
Clinical_trials
/
Etiology_studies
/
Risk_factors_studies
Limites:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Langue:
En
Journal:
Cerebrovasc Dis
Sujet du journal:
ANGIOLOGIA
/
CEREBRO
Année:
2001
Type de document:
Article
Pays d'affiliation:
Allemagne